D. E. Shaw & Co., Inc. Pfizer Inc Call Options Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$25.89 - $29.73 $8.52 Million - $9.78 Million	-329,000 Reduced 10.41%	2,832,600 $78.6 Million
Q4 2023 Feb 14, 2024	BUY	$26.13 - $33.94 $37.1 Million - $48.1 Million	1,418,500 Added 81.38%	3,161,600 $91 Million
Q3 2023 Nov 14, 2023	BUY	$32.09 - $37.51 $27.9 Million - $32.6 Million	869,100 Added 99.44%	1,743,100 $57.8 Million
Q2 2023 Aug 14, 2023	SELL	$36.12 - $41.79 $9.25 Million - $10.7 Million	-256,100 Reduced 22.66%	874,000 $32.1 Million
Q1 2023 May 15, 2023	SELL	$39.39 - $51.28 $39.1 Million - $50.9 Million	-991,800 Reduced 46.74%	1,130,100 $46.1 Million

Q4 2022 Feb 14, 2023	BUY	$41.75 - $54.5 $27.7 Million - $36.2 Million	663,900 Added 45.53%	2,121,900 $109 Million
Q3 2022 Nov 14, 2022	BUY	$43.76 - $53.42 $875,200 - $1.07 Million	20,000 Added 1.39%	1,458,000 $63.8 Million
Q2 2022 Aug 15, 2022	SELL	$46.53 - $55.17 $1.61 Million - $1.9 Million	-34,500 Reduced 2.34%	1,438,000 $75.4 Million
Q1 2022 May 16, 2022	BUY	$45.75 - $56.69 $12.6 Million - $15.6 Million	275,000 Added 22.96%	1,472,500 $76.2 Million
Q4 2021 Feb 14, 2022	BUY	$41.32 - $61.25 $12.6 Million - $18.7 Million	304,500 Added 34.1%	1,197,500 $70.7 Million
Q3 2021 Nov 15, 2021	SELL	$39.25 - $50.42 $16.4 Million - $21 Million	-417,000 Reduced 31.83%	893,000 $38.4 Million
Q2 2021 Aug 16, 2021	BUY	$35.91 - $40.68 $34.4 Million - $39 Million	958,000 Added 272.16%	1,310,000 $51.3 Million
Q1 2021 May 17, 2021	SELL	$33.49 - $37.77 $3.45 Million - $3.89 Million	-103,000 Reduced 22.64%	352,000 $12.8 Million
Q4 2020 Feb 16, 2021	BUY	$33.47 - $42.56 $4.35 Million - $5.53 Million	130,000 Added 40.0%	455,000 $16.7 Million
Q3 2020 Nov 16, 2020	BUY	$31.75 - $37.25 $5.56 Million - $6.52 Million	175,000 Added 116.67%	325,000 $11.9 Million
Q2 2020 Aug 14, 2020	SELL	$30.12 - $36.54 $13.6 Million - $16.5 Million	-452,700 Reduced 75.11%	150,000 $4.91 Million
Q1 2020 May 15, 2020	SELL	$27.03 - $38.62 $30.2 Million - $43.2 Million	-1,118,400 Reduced 64.98%	602,700 $19.7 Million
Q4 2019 Feb 14, 2020	BUY	$32.92 - $37.36 $35.3 Million - $40 Million	1,070,800 Added 164.66%	1,721,100 $67.4 Million
Q3 2019 Nov 14, 2019	BUY	$32.49 - $42.13 $12.4 Million - $16 Million	380,400 Added 140.94%	650,300 $23.4 Million
Q2 2019 Aug 14, 2019	SELL	$36.98 - $41.52 $13.5 Million - $15.2 Million	-365,000 Reduced 57.49%	269,900 $11.7 Million
Q1 2019 May 15, 2019	BUY	$37.5 - $41.2 $1.42 Million - $1.56 Million	37,800 Added 6.33%	634,900 $27 Million
Q4 2018 Feb 14, 2019	SELL	$38.47 - $43.86 $20.7 Million - $23.6 Million	-538,100 Reduced 47.4%	597,100 $26.1 Million
Q3 2018 Nov 14, 2018	BUY	$34.47 - $41.81 $29 Million - $35.2 Million	841,400 Added 286.39%	1,135,200 $50 Million
Q2 2018 Aug 14, 2018	SELL	$32.98 - $35.16 $23.1 Million - $24.6 Million	-700,200 Reduced 70.44%	293,800 $10.7 Million
Q4 2017 Feb 14, 2018	SELL	$33.26 - $35.29 $625,288 - $663,452	-18,800 Reduced 1.86%	994,000 $36 Million
Q3 2017 Nov 14, 2017	BUY	$31.0 - $34.15 $31.4 Million - $34.6 Million	1,012,800	1,012,800 $36.2 Million

Others Institutions Holding PFE

# of Institutions

3,159

Shares Held

3.68B

Call Options Held

67.4M

Put Options Held

113M

Vanguard Group Inc Valley Forge, PA

507M
Shares

$14.2 Billion
0.28% of portfolio
Black Rock Inc. New York, NY

431M
Shares

$12.1 Billion
0.28% of portfolio
State Street Corp Boston, MA

291M
Shares

$8.13 Billion
0.37% of portfolio
Wellington Management Group LLP Boston, MA

178M
Shares

$4.97 Billion
0.89% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

122M
Shares

$3.42 Billion
0.79% of portfolio

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $157B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account